Is It Safe to Use Repeated Low-level Red Light Therapy in Children with Myopia?

Abstract

[No abstract available in the source PDF. First paragraph follows.] 10.61474/ncs.2025.00020. Myopia is a major global public health concern, with China having one of the highest prevalence rates among children and adolescents.1 Among various strategies to prevent my opia progression and slow its development, repeated lowlevel red light (RLRL) therapy has emerged as a popular yet controversial option. Unlike photobiomodulation, which uti lizes low-energy light (including red and near-infrared light) to modulate cellular functions, RLRL therapy employs a specific wavelength of red light (typically 650 nm) to delay axial elongation and refractive error progression by enhancing cellular metabolism and energy supply. However, the rapid adoption of RLRL has raised challenges, including regula tory and safety concerns.